MedPageToday -- Women with ductal carcinoma in situ (DCIS) benefit long term from adjuvant radiation and tamoxifen in terms of reduced recurrence, although not survival, researchers affirmed. Radiotherapy after DCIS excision reduced risk of new breast events by 59% (P<0.0001) with an absolute 10-year reduction in local cancer recurrences of 12.3%, Jack Cuzick, MD, of Cancer Research UK in London, and colleagues reported online in Lancet Oncology.
